A recent clinical study concerning variants in NLRP3 inflammasomes revealed that the activation of NLRP3 inflammasomes could result in widespread release of proinflammatory cytokines and represent a risk factor for clinical symptoms in MS [20]. The gene discussed is NLRP3; the disease is myeloid sarcoma.